Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Cancer Res. 2019 Oct 16;18(1):166–178. doi: 10.1158/1541-7786.MCR-19-0204

Figure 5: PRMT6 is a novel regulator of ILF2 expression.

Figure 5:

A. Spearman rank correlation analysis of TCGA lung cancer datasets revealed a positive correlation between PRMT6 and ILF2. B. Protein lysates from human lung tumor and adjacent uninvolved lung tissue from the same patient were probed for the expression of PRMT6 and ILF2 via immunoblotting. C. Human non-transformed bronchial epithelial cells (Beas2B) were transfected with either control or HA-PRMT6. The cell lysates were later probed for the expression of PRMT6 (HA-tag) and ILF2 via immunoblotting. D, E. Lysates of H2122 (D) and H1299 (E) PRMT6 knockout clones and their parental cells were immunoblotted with anti-PRMT6 and anti-ILF2 antibodies. F. Tissue lysates from the lungs of PRMT6Tg; Sftpc-Cretm and PRMT6Tg control mice after tamoxifen and urethane treatments were subjected to immunoblotting with anti-PRMT6 and anti-ILF2 antibodies. G. Human non-transformed bronchial epithelial cells (Beas2B) were transfected with either HA-PRMT6 or HA-PRMT6-KLD mutant. The cell lysates were later probed for the expression of PRMT6 (HA-tag) and ILF2 via immunoblotting. H. The proliferation rates of H1299 cells co-transfected with siRNA-resistant HA-ILF2 plasmid with either control or ILF2 siRNAs were determined by clonogenic cell proliferation assays as described in the methods. The cell lysates were later probed for the expression of ILF2 via immunoblotting. **, p< 0.01; *, p< 0.05. I. The proliferation rates of Beas2B cells co-transfected with HA-PRMT6 plasmid with either control or ILF2 siRNAs were determined by hematocytometer cell count as described in the methods. The cell lysates were later probed for the expression of HA-PRMT6 and ILF2 via immunoblotting. **, p< 0.01.